Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $62.6 million.

  • Fulcrum Therapeutics' Shares Outstanding (Weighted Average) rose 30.12% to $62.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.6 million, marking a year-over-year increase of 30.12%. This contributed to the annual value of $61984.0 for FY2024, which is 109.93% up from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Shares Outstanding (Weighted Average) of $62.6 million as of Q3 2025, which was up 30.12% from $62.5 million recorded in Q2 2025.
  • Fulcrum Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $62.6 million during Q3 2025, with a 5-year trough of $32636.0 in Q2 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $27.9 million, with a median of $61984.0 in 2024.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Shares Outstanding (Weighted Average) plummeted by 9987.1% in 2022, and later skyrocketed by 15102252.38% in 2023.
  • Fulcrum Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $35361.0 in 2021, then rose by 27.23% to $44991.0 in 2022, then skyrocketed by 36.27% to $61310.0 in 2023, then rose by 1.1% to $61984.0 in 2024, then soared by 100888.96% to $62.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $62.6 million for Q3 2025, versus $62.5 million for Q2 2025 and $62.5 million for Q1 2025.